Recombinant SARS-CoV-2, S1 Subunit Protein (RBD)

Lateral flow, indirect ELISA, sandwich ELISA, glycosylation analysis, binding assay, antibody generation, hybridoma screening, western blotting, biotin/dye/bead conjugation, binder selection, crystallization, and vaccine development. Sandwich ELISA: this protein functions as a standard in conjunction with 130-10815 (capture antibody) and 130-10814 (detection antibody).

C-terminal his-tag

-20°C

Recombinant SARS-CoV-2, S1 Subunit Protein (RBD) with C-terminal His tag, derived from the transfected human HEK293 cells. Datasheet

12352202

Arg319-Phe541

His-tag affinity purification by immobilized metal ion affinity chromatography (IMAC)

Figure 1. Deglycosylation of purified recombinant proteins. Purified proteins were untreated (Lane 2) or treated with Protein Deglycosylation Kit under native (Lane 3) or reducing (Lane 4) conditions. Deglycosylation treatment resulted in a mobility shift of the protein to produce one major band at the expected size, thus indicating that the untreated recombinant protein (Lane 2) was glycosylated. Lane 1: Protein standard ladder (kDa) Lane 2: Untreated protein under reducing conditions Lane 3: Treated protein with deglycosylation enzymes under native conditions Lane 4: Treated protein with deglycosylation enzymes under reducing conditions.

Product binding ability was measured by ELISA. The immobilized recombinant human ACE2 protein (Catalog #230-30165, coated at 0.5 ug/ml, 100 ul/well) was incubated with the serial diluted SARS CoV-2 S1 RBD wild type protein (Catalog #230-30162). The bound protein was detected by mouse anti-S1 RBD monoclonal antibody using ELISA. The calculated EC50 is 32.77 ng/ml.